BioCryst Pharmaceuticals (BCRX) : Traders are bullish on BioCryst Pharmaceuticals (BCRX) as it has outperformed the S&P 500 by a wide margin of 4.9% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 2.23%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.77% in the last 1 week, and is up 2.77% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 3% and the 50-Day Moving Average is 13.47%.The 200 Day SMA reached 1.33% BioCryst Pharmaceuticals, Inc. is up 58.93% in the last 3-month period. Year-to-Date the stock performance stands at -56.88%.
BioCryst Pharmaceuticals (BCRX) : The consensus price target for BioCryst Pharmaceuticals (BCRX) is $6.33 for the short term with a standard deviation of $2.88. The most optimist securities analyst among the 6 who monitor the stock believes that the stock can reach $10, however, the pessimist price target for the company is $3.
Company shares have received an average consensus rating of Hold for the current week BioCryst Pharmaceuticals (NASDAQ:BCRX): stock was range-bound between the intraday low of $4.33 and the intraday high of $4.5 after having opened at $4.5 on Fridays session. The stock finally closed in the red at $4.5, a loss of -1.33%. The stock remained in the red for the whole trading day. The total traded volume was 1,088,640 shares. The stock failed to cross $4.5 in Fridays trading. The stocks closing price on Thursday was $4.45.
BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its products include RAPIVAB, BCX4161, BCX7353 and other second generation HAE compounds, BCX4430 and Forodesine. Peramivir is an intravenous neuraminidase inhibitor approved in multiple countries for the treatment of patients with influenza, in the United States as RAPIVAB, in Japan as RAPIACTA and in Korea as PERAMIFLU. BCX4161 is the Companys Hereditary Angioedema (HAE) product candidate. BCX7353 is a plasma kallikrein inhibitor. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor.